(firstQuint)A First-in-Human Study of BNZ132-1-40.

 This is a open-label study of single doses of intravenous BNZ132-1-40 administered to healthy adult subjects.

 Subjects are followed for 30 days after treatment for collection of safety, PK and PD data.

 Cohorts of up to 6 subjects will be enrolled for each dose level.

.

 A First-in-Human Study of BNZ132-1-40@highlight

This is an open-label, single ascending dose study to characterize the safety and PK/PD profile of IV BNZ132-1-40, a novel peptide inhibitor of multiple cytokines in the IL-2 family.

